Verastem Inc (VSTM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Verastem Inc (VSTM) has a cash flow conversion efficiency ratio of -0.637x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.12 Million) by net assets ($81.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Check VSTM strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Verastem Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how Verastem Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. See Verastem Inc net assets for net asset value and shareholders' equity analysis.
Verastem Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Verastem Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TECSYS Inc.
TO:TCS
|
0.085x |
|
Jacquet Metal Service SA
PA:JCQ
|
0.059x |
|
GSI Technology Inc
NASDAQ:GSIT
|
-0.096x |
|
Robo.ai Inc.
NASDAQ:AIIO
|
0.060x |
|
Real Brokerage Inc
NASDAQ:REAX
|
0.355x |
|
SNDL Inc.
NASDAQ:SNDL
|
0.029x |
|
Taiwan Steel Union Co Ltd
TW:6581
|
0.035x |
|
Altimmune Inc
NASDAQ:ALT
|
-0.086x |
Annual Cash Flow Conversion Efficiency for Verastem Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of Verastem Inc from 2010 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Verastem Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $57.20 Million | $-137.51 Million | -2.404x | -166.30% |
| 2024-12-31 | $-28.89 Million | $-104.77 Million | 3.626x | +340.63% |
| 2023-12-31 | $57.37 Million | $-86.46 Million | -1.507x | -12.16% |
| 2022-12-31 | $47.39 Million | $-63.67 Million | -1.344x | -119.88% |
| 2021-12-31 | $87.56 Million | $-53.50 Million | -0.611x | -110.22% |
| 2020-12-31 | $115.27 Million | $-33.51 Million | -0.291x | +98.49% |
| 2019-12-31 | $7.17 Million | $-138.52 Million | -19.308x | -3120.84% |
| 2018-12-31 | $124.30 Million | $-74.52 Million | -0.599x | +39.66% |
| 2017-12-31 | $57.68 Million | $-57.31 Million | -0.994x | -143.62% |
| 2016-12-31 | $72.30 Million | $-29.48 Million | -0.408x | +8.28% |
| 2015-12-31 | $102.47 Million | $-45.56 Million | -0.445x | -6.95% |
| 2014-12-31 | $88.77 Million | $-36.90 Million | -0.416x | -85.61% |
| 2013-12-31 | $117.45 Million | $-26.30 Million | -0.224x | +10.35% |
| 2012-12-31 | $90.47 Million | $-22.60 Million | -0.250x | -131.48% |
| 2011-12-31 | $-12.77 Million | $-10.13 Million | 0.794x | +878.28% |
| 2010-12-31 | $3.24 Million | $-330.00K | -0.102x | -- |
About Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, which is an orally administered, small molecule dual RAF/MEK inhibitor developed to block MEK kinase activity and the compensatory reactivation of MEK by upstream RAF, thereby targeting the RAS/MAP… Read more